Clinical trials: Pancreatic Fibrosis
Cystic Fibrosis, Pancreatic Insufficiency
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
The specific aims for this study are: 1. To determine if sonographic findings predict the risk of progression of liver disease to cirrhosis by comparing cystic fibrosis subjects with heterogeneous echogenicity pattern on…
- Trial name
- PUSH (NCT01144507)
- Testing
- Abdominal Ultrasound, Sample collection procedures
- Where
- 11 sites in United States, Canada
- Volunteers
- 774 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Muscle Strength, Healthy
Reference Equations and Normative Data for Isometric Quadriceps and Handgrip Muscles STrength in Southern European Populations - RESTart: a Multicentre Study
This observational study aims to learn about peripheral muscle strength in healthy adults and people with chronic respiratory diseases.
- Conditions
- Muscle Strength, Healthy, Chronic Respiratory Diseases
- Trial name
- RESTart (NCT07628530)
- Where
- Spain
- Volunteers
- 2,815 people, healthy volunteers welcome
- Sponsor
- University of Alcala
Cystic Fibrosis
Parameters to Assess Response to Intra-Venous Antibiotic Treatment for Pulmonary Exacerbations in Cystic Fibrosis
Cystic fibrosis (CF) is a multisystem disease characterized by viscid secretions in multiple organ systems. Lung infection and damage account for most of the disease burden.
- Trial name
- PRIVATE (NCT04016571)
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- Belfast Health and Social Care Trust
Cystic Fibrosis, Lung Diseases
Gene Modifiers of Cystic Fibrosis Lung Disease
The purpose of this study is to examine genetic modifiers of the severity of cystic fibrosis lung disease.
- Trial name
- NCT00037765
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- University of North Carolina, Chapel Hill
Cystic Fibrosis
The Addition of Non-Invasive Ventilation To Airway Clearance Techniques In Adults With Cystic Fibrosis
Cystic Fibrosis (CF) is a genetic disorder of altered ion transport across cell membranes which is characterised by the production of thickened bodily secretions, affecting the function of organs such as the pancreas and the…
- Trial name
- NIV (NCT01885650)
- Testing
- Airway Clearance Techniques
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Cystic Fibrosis (CF), Primary Ciliary Dyskinesia (PCD)
Upper Extremity Exercise Capacity, Muscle Oxygenation, and Balance in Pediatric CF and PCD
The number of studies evaluating respiratory functions and upper extremity functional exercise capacity in patients with CF and PCD is limited in the literature.
- Trial name
- NCT07148362
- Where
- Turkey (Türkiye)
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Gazi University
Cystic Fibrosis, Cystic Fibrosis-related Diabetes
Cardiac Structure and Function in Patients with Cystic Fibrosis
In a prospective observational cohort study (n = 100), the investigators aim to assess the correlation between cardiac biomarkers, advanced echocardiography and cystic fibrosis genotype and severity and determine whether these…
- Conditions
- Cystic Fibrosis, Cystic Fibrosis-related Diabetes, Cystic Fibrosis, Pulmonary, Cystic Fibrosis of Pancreas
- Trial name
- NCT06084468
- Where
- 2 sites in Denmark
- Volunteers
- 104 people
- Sponsor
- Herlev and Gentofte Hospital
Cystic Fibrosis
Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)
The prevalence of methicillin resistant Staphylococcus aureus (MRSA) respiratory infection in Cystic Fibrosis (CF) has increased dramatically over the last decade.
- Trial name
- PMEP (NCT01594827)
- Testing
- Inhaled Vancomycin, Rifampin, Trimethoprim/Sulfamethoxazole (TMP/SMX)
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Johns Hopkins University
Cystic Fibrosis
Effects of a Partially Supervised Conditioning Program in CF
Physical activity and exercise have become an accepted and valued component of Cystic Fibrosis care. Regular physical activity and exercise can slow the rate of decline of pulmonary function, improve physical fitness, and enhance…
- Trial name
- ACTIVATE-CF (NCT01744561)
- Testing
- Exercise Intervention
- Where
- 28 sites in United States, Austria and 6 more
- Volunteers
- 155 people
- Sponsor
- Wuerzburg University Hospital
Cystic Fibrosis in Children
The Effect of Telenursing on Self-efficacy and Treatment Adherence in Children With Cystic Fibrosis
The goal of this clinical trial is to learn if a telenursing-based programs works to increase self-efficacy and treatment adherence in children with Cystic fibrosis disease.
- Trial name
- NCT06660745
- Testing
- telenursing-based family empowerment program
- Where
- Iran
- Volunteers
- 50 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Cystic Fibrosis
Improving Therapeutic Adherence With a Co-constructed Program Involving Both Patients and Health Care Professionals
Background Cystic fibrosis is a life-threatening genetic disorder responsible for pulmonary failure and multi-systemic complications involving specific and large medical care burden.
- Trial name
- NCT03226795
- Testing
- " Information-Motivation-Behavioral skills " intervention.
- Where
- 3 sites in France
- Volunteers
- 450 people
- Sponsor
- Hospices Civils de Lyon
Cystic Fibrosis
Identification of Dysglycemia With Continuous Glucose Monitoring to Assess Clinical Evolution in Cystic Fibrosis
Cystic fibrosis (CF)-related diabetes (CFRD) is the most important emerging complication after pulmonary complications. This specific form of diabetes is associated with an increased morbidity and mortality.
- Trial name
- ProspeC-F (NCT05099939)
- Where
- 4 sites in Canada, France
- Volunteers
- 121 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Cystic Fibrosis, Motor Neuron Disease
MN4000 for Treatment of CF and MND Patients in the Home Setting
The study was a non-randomized open label pilot study. It was an observational design conducted at one (1) site in the US. All enrolled subjects received treatment with the MN4000.
- Conditions
- Cystic Fibrosis, Motor Neuron Disease, Airway Clearance Impairment
- Trial name
- NCT03797677
- Testing
- MN 4000
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Hill-Rom
Cystic Fibrosis
Cystic Fibrosis (CF) Flow Rates Study
We wish to measure the inspiratory flow and volumes generated by the subjects inhaling from a spirometer with a high resistance dry powder inhaler in series in subjects with cystic fibrosis.
- Trial name
- NCT00779077
- Volunteers
- 25 people
- Sponsor
- Syntara
Cystic Fibrosis
Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients
The purpose of this study is to prolong the time to reinfection with Pseudomonas aeruginosa after successfully treated acute or intermittent infection.
- Trial name
- PsAer-IgY (NCT01455675)
- Testing
- IgY
- Where
- 42 sites in Austria, Belgium and 7 more
- Volunteers
- 164 people
- Sponsor
- Mukoviszidose Institut gGmbH
Cystic Fibrosis
Bone Microarchitecture in Young Cystic Fibrosis Patients
Patients with cystic fibrosis are at risk of developing low bone mineral density (BMD) potentially leading to pathological fractures at adult age.
- Trial name
- NCT01788267
- Testing
- scan examination HR-pQCT
- Where
- France
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Cystic Fibrosis
Growth Hormone Use in Cystic Fibrosis - a Multicenter Study
Cystic Fibrosis (CF) is the most common lethal genetic disorder in America. Previous studies by our group and others have shown that human recombinant growth hormone (GH) improves height velocity, weight velocity, lean body mass…
- Trial name
- NCT00005112
- Testing
- Human recombinant growth hormone
- Where
- 2 sites in United States
- Sponsor
- National Center for Research Resources (NCRR)
Cystic Fibrosis
Growth Hormone Use in Adolescents and Adults With Cystic Fibrosis
We hypothesize that the anabolic effects of growth hormone (GH) will improve the clinical status of patients with CF by improving lean body mass, osteopenia, muscle strength, pulmonary function, and quality of life.
- Trial name
- NCT00287430
- Testing
- Growth Hormone, Whole body Protein Turnover Study, Dual Energy X-ray Absorptiometry (DEXA)
- Sponsor
- University of Texas Southwestern Medical Center
Cystic Fibrosis
Safety, Tolerability, and Pharmacokinetics of PTI-808, PTI-801, and PTI-428 Combination Therapy in Subjects With Cystic Fibrosis
The study is a randomized, double-blind, placebo-controlled, study that will be conducted at multiple centers in subjects with Cystic Fibrosis (CF) who are either homozygous for the F508del mutation or heterozygous with at least…
- Trial name
- NCT03500263
- Testing
- PTI-808, PTI-801, PTI-428
- Where
- 4 sites in United Kingdom
- Volunteers
- 12 people
- Sponsor
- Proteostasis Therapeutics, Inc.
Cystic Fibrosis
A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation
The purpose of this study is to evaluate the efficacy and safety of VX-661 in combination with ivacaftor (IVA, VX-770) and IVA monotherapy in participants with Cystic Fibrosis (CF) who are heterozygous for F508del-CFTR allele and…
- Trial name
- NCT02392234
- Testing
- VX-661/Ivacaftor, Ivacaftor
- Where
- 93 sites in United States, Australia and 9 more
- Volunteers
- 248 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.